Generalized Linear Porokeratosis Treated With Ixekizumab

Yihe Zheng1, Yunhao Zhu2, Jianjun Qiao1

  • 1Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

The Journal of Dermatology
|December 12, 2025
PubMed

Insights

Ixekizumab effectively treated extensive linear porokeratosis (LP) in a young patient, achieving near-complete lesion clearance. While skin lesions responded well, nail dystrophy showed limited improvement, suggesting targeted therapy potential for refractory LP.

Area of Science:

  • Dermatology
  • Immunology
  • Clinical Therapeutics

Background:

  • Linear porokeratosis (LP) is a rare, chronic skin disorder.
  • Treatment options for extensive or refractory LP are limited.
  • The role of interleukin-17A (IL-17A) in LP pathogenesis is under investigation.